Editas Medicine Stock Forecast, Price & News

Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

Is Editas Medicine a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 3 sell ratings, 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine or view top-rated stocks.

How has Editas Medicine's stock price been impacted by COVID-19 (Coronavirus)?

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EDIT shares have increased by 59.7% and is now trading at $32.37.
View which stocks have been most impacted by COVID-19.

Are investors shorting Editas Medicine?

Editas Medicine saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 10,160,000 shares, an increase of 47.2% from the September 30th total of 6,900,000 shares. Based on an average daily volume of 1,760,000 shares, the days-to-cover ratio is presently 5.8 days.
View Editas Medicine's Short Interest.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Editas Medicine.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings data on Monday, November, 8th. The company reported ($0.57) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.81) by $0.24. The business had revenue of $6.20 million for the quarter, compared to analyst estimates of $4.92 million. Editas Medicine had a negative trailing twelve-month return on equity of 38.28% and a negative net margin of 871.91%. The business's revenue was down 90.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.12 EPS.
View Editas Medicine's earnings history.

What price target have analysts set for EDIT?

17 Wall Street analysts have issued 1-year price objectives for Editas Medicine's stock. Their forecasts range from $20.00 to $86.00. On average, they anticipate Editas Medicine's share price to reach $57.27 in the next year. This suggests a possible upside of 76.9% from the stock's current price.
View analysts' price targets for Editas Medicine or view top-rated stocks among Wall Street analysts.

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:

• James C. Mullen, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• Harry R. Gill, Senior Vice President-Operations
• Michelle Robertson, Treasurer, Chief Financial & Accounting Officer
• Lisa A. Michaels, Chief Medical Officer & Executive Vice President (LinkedIn Profile)
• Mark S. Shearman, Chief Scientific Officer & Executive VP

Who are some of Editas Medicine's key competitors?

Some companies that are related to Editas Medicine include Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Exelixis (EXEL), Beam Therapeutics (BEAM), Abcam (ABCM), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Sana Biotechnology (SANA) and SpringWorks Therapeutics (SWTX).
View all of EDIT's competitors.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.98%), Sumitomo Mitsui Trust Holdings Inc. (6.24%), Nikko Asset Management Americas Inc. (6.24%), Geode Capital Management LLC (1.75%), Victory Capital Management Inc. (1.64%) and Morgan Stanley (1.33%). Company insiders that own Editas Medicine stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Lisa Anne Michaels and Michelle Robertson.
View institutional ownership trends for Editas Medicine.

Which institutional investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Two Sigma Advisers LP, BlackRock Inc., Lombard Odier Asset Management Switzerland SA, DDD Partners LLC, Credit Suisse AG, and Citigroup Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Bruce Eaton, Charles Albright, James C Mullen, Lisa Anne Michaels, and Michelle Robertson.
View insider buying and selling activity for Editas Medicine or view top insider-selling stocks.

Which institutional investors are buying Editas Medicine stock?

EDIT stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Lord Abbett & CO. LLC, Citadel Advisors LLC, IMC Chicago LLC, Jane Street Group LLC, Voloridge Investment Management LLC, Eagle Asset Management Inc., and Two Sigma Investments LP.
View insider buying and selling activity for Editas Medicine or or view top insider-buying stocks.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $32.37.

How much money does Editas Medicine make?

Editas Medicine has a market capitalization of $2.21 billion and generates $90.73 million in revenue each year. The company earns $-115.98 million in net income (profit) each year or ($3.24) on an earnings per share basis.

How many employees does Editas Medicine have?

Editas Medicine employs 235 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

Where are Editas Medicine's headquarters?

Editas Medicine is headquartered at 11 Hurley Street, Cambridge MA, 02141.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at (617) 401-9000 or via email at [email protected].